Background:Atrial fibrillation (AF) is the most common tachyarrhythmia, affecting up to 4% of the general population. Susceptibility to AF episodes can be explained by various risk factors (RF) that alter the substrate of the left atrium. Association between several RF and AF development and recurrence has been demonstrated in several studies. Areas of uncertainty: Treatment strategies depend on patients' characteristics and comorbidities. Medical literature and consensus documents recommend an integrated approach, but also identify evidence gaps in treating patients with severe comorbidities. Data sources: Literature search was performed using PubMed electronic database. We used the following terms as key words: atrial fibrillation, risk factors, comorbidities, primary prevention, secondary prevention. Results: Active intervention helps control the burden of AF and increase the chances of a positive outcome on the long term. Aggressive control and individualized treatment of most prevalent modifiable risk factors can reduce the risk of atrial fibrillation. Optimization of treatment strategy should be performed periodically, since RF and comorbidities are dynamic and often evolve. Conclusion: Personalized strategies should be applied to each patient after careful assessment of individual risk. A personalized approach is indicated to both reduce the burden of AF and improve symptoms, quality of life and survival. Close attention to details is required to avoid disease and therapy related complications in the presence of comorbidities.
Background:Atrial fibrillation (AF) is the most common tachyarrhythmia, affecting up to 4% of the general population. Susceptibility to AF episodes can be explained by various risk factors (RF) that alter the substrate of the left atrium. Association between several RF and AF development and recurrence has been demonstrated in several studies. Areas of uncertainty: Treatment strategies depend on patients' characteristics and comorbidities. Medical literature and consensus documents recommend an integrated approach, but also identify evidence gaps in treating patients with severe comorbidities. Data sources: Literature search was performed using PubMed electronic database. We used the following terms as key words: atrial fibrillation, risk factors, comorbidities, primary prevention, secondary prevention. Results: Active intervention helps control the burden of AF and increase the chances of a positive outcome on the long term. Aggressive control and individualized treatment of most prevalent modifiable risk factors can reduce the risk of atrial fibrillation. Optimization of treatment strategy should be performed periodically, since RF and comorbidities are dynamic and often evolve. Conclusion: Personalized strategies should be applied to each patient after careful assessment of individual risk. A personalized approach is indicated to both reduce the burden of AF and improve symptoms, quality of life and survival. Close attention to details is required to avoid disease and therapy related complications in the presence of comorbidities.
Authors: Peter M Okin; Kristian Wachtell; Richard B Devereux; Katherine E Harris; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Lars H Lindholm; Markku S Nieminen; Jonathan M Edelman; Darcy A Hille; Björn Dahlöf Journal: JAMA Date: 2006-09-13 Impact factor: 56.272
Authors: Andreas Goette; Norbert Schön; Paulus Kirchhof; Günter Breithardt; Thomas Fetsch; Karl Georg Häusler; Helmut U Klein; Gerhard Steinbeck; Karl Wegscheider; Thomas Meinertz Journal: Circ Arrhythm Electrophysiol Date: 2011-12-07
Authors: Gary F Mitchell; Ramachandran S Vasan; Michelle J Keyes; Helen Parise; Thomas J Wang; Martin G Larson; Ralph B D'Agostino; William B Kannel; Daniel Levy; Emelia J Benjamin Journal: JAMA Date: 2007-02-21 Impact factor: 56.272
Authors: L Julian Haywood; Charles E Ford; Richard S Crow; Barry R Davis; Barry M Massie; Paula T Einhorn; Angela Williard Journal: J Am Coll Cardiol Date: 2009-11-24 Impact factor: 24.094
Authors: Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray Journal: Circulation Date: 2013-12-17 Impact factor: 29.690
Authors: Roland E Schmieder; Sverre E Kjeldsen; Stevo Julius; Gordon T McInnes; Alberto Zanchetti; Tsushung A Hua Journal: J Hypertens Date: 2008-03 Impact factor: 4.844
Authors: Ali H Hachem; Joseph E Marine; Housam A Tahboub; Sana Kamdar; Shaffi Kanjwal; Ronak Soni; Khalil Kanjwal Journal: Cardiol Res Pract Date: 2018-04-01 Impact factor: 1.866